Description
30mg is supplied as three separate 10 mg vials to enhance stability. Reconstituting each vial only when needed helps maintain purity and allows for easier, more precise volume preparation.
an investigational once-weekly injectable peptide that acts as a triple agonist, targeting GIP, GLP-1, and glucagon receptors. It induces significant weight loss—up to 24% over 48 weeks in trials—by reducing appetite, slowing digestion, and increasing metabolism.Â
-
- Mechanism of Action: Known as a triple-agonist, it mimics three natural hormones (GIP, GLP-1, and Glucagon) to improve glycemic control and maximize metabolic effects (energy expenditure and fat reduction).
- Effectiveness: Phase 2 studies showed that 48 weeks of treatment led to an average weight loss of 24.4%
. It is considered a potential next-generation weight loss therapy.
- Administration: It is designed to be a once-weekly subcutaneous injection.
- Common Side Effects: Consistent with the GLP-1 class, side effects are primarily gastrointestinal, including nausea, vomiting, and diarrhea.Â
Differences from Current Medications
While popular, current drugs (semaglutide) and (tirzepatide) target one or two receptors, respectively, whereas retatrutide’s addition of the glucagon receptor agonism is aimed at increasing energy expenditure.Â
- Contraindications: Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use it.
Other Risks: Potential for hypoglycemia, particularly if used with other diabetes medications.
patients reach and maintain lower HbA1c and weight levels.Â
Disclaimer: This information is for educational purposes based on research studies and does not constitute medical advice. Consult a healthcare provider before starting any peptide therapy.
Reviews
There are no reviews yet.